MX2021013311A - Sistemas de suministro nanovesiculares hipoinmunitarios adaptados para tumores cancerosos. - Google Patents

Sistemas de suministro nanovesiculares hipoinmunitarios adaptados para tumores cancerosos.

Info

Publication number
MX2021013311A
MX2021013311A MX2021013311A MX2021013311A MX2021013311A MX 2021013311 A MX2021013311 A MX 2021013311A MX 2021013311 A MX2021013311 A MX 2021013311A MX 2021013311 A MX2021013311 A MX 2021013311A MX 2021013311 A MX2021013311 A MX 2021013311A
Authority
MX
Mexico
Prior art keywords
bionvs
hypo
individual
cancer
tailored
Prior art date
Application number
MX2021013311A
Other languages
English (en)
Inventor
Thomas Malcolm
Original Assignee
Thomas Malcolm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Malcolm filed Critical Thomas Malcolm
Publication of MX2021013311A publication Critical patent/MX2021013311A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nanovesículas biomiméticas hipoinmunogénicas derivadas de células madre pluripotentes inducidas (iPSC) (hypo-bioNV), que incluyen receptores de antígenos quiméricos (CAR) adaptados, que pueden reconocer biomarcadores diana a través de un fragmento de anticuerpo de la región scFV o mediante un receptor de reconocimiento de epítopos víricos (VERR). Un método de fabricación de las hypo-bioNV. Un método de tratamiento de un individuo con cáncer, mediante la administración de las hypo-bioNV a un individuo, el direccionamiento a las células cancerosas y el tratamiento del cáncer. Un método de direccionamiento a las células de un individuo, mediante la administración de las hypo-bioNV a un individuo y el direccionamiento a las células que han de destruirse o tratarse.
MX2021013311A 2019-05-06 2020-05-06 Sistemas de suministro nanovesiculares hipoinmunitarios adaptados para tumores cancerosos. MX2021013311A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962843713P 2019-05-06 2019-05-06
PCT/US2020/031616 WO2020227369A1 (en) 2019-05-06 2020-05-06 Tailored hypoimmune nanovesicular delivery systems for cancer tumors

Publications (1)

Publication Number Publication Date
MX2021013311A true MX2021013311A (es) 2022-02-11

Family

ID=73051669

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013311A MX2021013311A (es) 2019-05-06 2020-05-06 Sistemas de suministro nanovesiculares hipoinmunitarios adaptados para tumores cancerosos.

Country Status (10)

Country Link
US (1) US20220218842A1 (es)
EP (1) EP3965829A4 (es)
JP (1) JP7479399B2 (es)
KR (1) KR20220004175A (es)
CN (1) CN113924126A (es)
AU (1) AU2020267758B2 (es)
CA (1) CA3139287A1 (es)
IL (1) IL287734A (es)
MX (1) MX2021013311A (es)
WO (1) WO2020227369A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022250880A1 (en) * 2021-05-25 2022-12-01 Malcolm Thomas Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
EP4355304A1 (en) * 2021-06-17 2024-04-24 Malcolm, Thomas Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
US20230144704A1 (en) * 2021-11-05 2023-05-11 Thomas Malcolm Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
WO2023230568A2 (en) * 2022-05-25 2023-11-30 Malcolm Thomas Hypoimmunogenic cells for generating biomimetic nanovesicles
WO2023230231A1 (en) * 2022-05-25 2023-11-30 Malcolm Thomas Controlled expression of therapeutically relevant biomolecules for lumen-localized payloads in biomimetic nanovesicles and exosomes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447079A1 (de) 2003-02-15 2004-08-18 Fraunhofer-Gesellschaft für angewandte Forschung e.V. Vesikel mit chimären Rezeptoren zur Induktion einer gerichteten T-Zellantwort in vivo
EP3253866A1 (en) 2015-02-06 2017-12-13 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
CN108990413A (zh) 2015-08-12 2018-12-11 麻省理工学院 纳米颗粒的细胞表面偶联
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
CN108175759B (zh) * 2016-12-08 2021-03-19 暨南大学 一种抗肿瘤靶向给药系统及其制备方法与应用
US11851659B2 (en) 2017-03-22 2023-12-26 Novartis Ag Compositions and methods for immunooncology
WO2018208728A1 (en) * 2017-05-08 2018-11-15 Flagship Pioneering, Inc. Compositions for facilitating membrane fusion and uses thereof
US20210187040A1 (en) * 2017-09-01 2021-06-24 Orig3N, Inc. Ipsc-derived secretome compositions, and related systems and methods

Also Published As

Publication number Publication date
IL287734A (en) 2021-12-01
JP7479399B2 (ja) 2024-05-08
JP2022531473A (ja) 2022-07-06
EP3965829A1 (en) 2022-03-16
WO2020227369A1 (en) 2020-11-12
EP3965829A4 (en) 2023-05-24
AU2020267758B2 (en) 2023-11-23
AU2020267758A1 (en) 2021-11-25
CA3139287A1 (en) 2020-11-12
CN113924126A (zh) 2022-01-11
KR20220004175A (ko) 2022-01-11
US20220218842A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
MX2021013311A (es) Sistemas de suministro nanovesiculares hipoinmunitarios adaptados para tumores cancerosos.
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
BR112019009316A2 (pt) anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie.
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
BR112019007714A2 (pt) anticorpos de 4-1bb anti-humanos e usos dos mesmos
WO2017193094A8 (en) Dna monoclonal antibodies targeting checkpoint molecules
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
BR112018010385A2 (pt) anticorpo, receptor de antígeno quimérico, ácido nucleico, célula recombinante, processo para produção de um anticorpo ou um receptor de antígeno quimérico, composição, e, método para detecção de uma célula que expressa cll-1, para diagnóstico de uma doença, para inibição de divisão da célula e para tratamento de um câncer.
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
PH12018502354A1 (en) Anti-c5 antibodies and methods of use
NZ631197A (en) Anti sez6 antibodies and methods of use
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
MX2021001516A (es) Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores.
ECSP12012138A (es) Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello
MX2019012606A (es) Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.
MX2022001942A (es) Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2022005821A (es) Terapia del carcinoma de celulas renales (rcc) usando linfocitos t modificados por ingenieria genetica dirigidos a cd70.
MX2022005816A (es) Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70.
MX2021012767A (es) Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
MX2017013177A (es) Anticuerpo anti-vegfr2 humano para terapia del cancer anti-angiogenica y dirigida.
MX2021000783A (es) Anticuerpos humanizados contra psma.